[go: up one dir, main page]

BRPI0818065A8 - Quimioterapêutco derivado de indazol cristalino - Google Patents

Quimioterapêutco derivado de indazol cristalino

Info

Publication number
BRPI0818065A8
BRPI0818065A8 BRPI0818065A BRPI0818065A BRPI0818065A8 BR PI0818065 A8 BRPI0818065 A8 BR PI0818065A8 BR PI0818065 A BRPI0818065 A BR PI0818065A BR PI0818065 A BRPI0818065 A BR PI0818065A BR PI0818065 A8 BRPI0818065 A8 BR PI0818065A8
Authority
BR
Brazil
Prior art keywords
crystalline
indazole
chemotherapeutic
derivative
same
Prior art date
Application number
BRPI0818065A
Other languages
English (en)
Inventor
B Borchardt Thomas
Chu-Kung Alexander
J Rozema Michael
V Bordawekar Shailendra
Original Assignee
Abbott Lab
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40090209&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0818065(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab, Abbvie Inc filed Critical Abbott Lab
Publication of BRPI0818065A2 publication Critical patent/BRPI0818065A2/pt
Publication of BRPI0818065A8 publication Critical patent/BRPI0818065A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

QUIMIOTERAPÊUTICO DERIVADO DE INDAZOL CRISTALINO. São reveladas Forma 1 Cristalina do Hidrato de N-[4-(3-amino-1H-indazol-4-il)fenil)- N'-(2-flúor-5-metilfenil)uréia, maneiras de fabricação, formulações compreendendo e fabricadas com a mesma além de métodos para tratamento de pacientes apresentando doença e fazendo uso da mesma.
BRPI0818065A 2007-10-19 2008-10-16 Quimioterapêutco derivado de indazol cristalino BRPI0818065A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98123607P 2007-10-19 2007-10-19
PCT/US2008/080061 WO2009052226A1 (en) 2007-10-19 2008-10-16 Crystalline indazole-derived chemotherepeutic

Publications (2)

Publication Number Publication Date
BRPI0818065A2 BRPI0818065A2 (pt) 2015-03-31
BRPI0818065A8 true BRPI0818065A8 (pt) 2016-03-08

Family

ID=40090209

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0818065A BRPI0818065A8 (pt) 2007-10-19 2008-10-16 Quimioterapêutco derivado de indazol cristalino

Country Status (24)

Country Link
US (2) US7947843B2 (pt)
EP (1) EP2195298B1 (pt)
JP (1) JP5517940B2 (pt)
KR (1) KR20100085116A (pt)
CN (1) CN101827822B (pt)
AR (1) AR068917A1 (pt)
AU (1) AU2008312529A1 (pt)
BR (1) BRPI0818065A8 (pt)
CA (1) CA2699352C (pt)
CL (1) CL2008003090A1 (pt)
CO (1) CO6280481A2 (pt)
CR (1) CR11388A (pt)
DO (1) DOP2010000115A (pt)
EC (1) ECSP10010188A (pt)
ES (1) ES2460951T3 (pt)
MX (1) MX2010004286A (pt)
PA (1) PA8800201A1 (pt)
PE (1) PE20091385A1 (pt)
RU (1) RU2010119928A (pt)
SG (1) SG185327A1 (pt)
TW (1) TW200934485A (pt)
UA (1) UA99746C2 (pt)
UY (1) UY31407A1 (pt)
WO (1) WO2009052226A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947843B2 (en) * 2007-10-19 2011-05-24 Abbott Laboratories Crystalline chemotherapeutic
US8759538B1 (en) 2013-06-13 2014-06-24 Abbvie Inc. Crystalline chemotherapeutic

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0410745A (pt) * 2003-05-22 2006-06-27 Abbott Lab inibidores de indazol, benzisoxazol e benzisotiazol quinase
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
WO2007015569A1 (ja) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
US9006240B2 (en) * 2005-08-02 2015-04-14 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
EP1959926A1 (en) 2005-10-25 2008-08-27 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
EP1962803A1 (en) * 2005-12-23 2008-09-03 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
EP2089003A1 (en) * 2006-11-09 2009-08-19 Abbott GmbH & Co. KG Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
US7947843B2 (en) * 2007-10-19 2011-05-24 Abbott Laboratories Crystalline chemotherapeutic

Also Published As

Publication number Publication date
PE20091385A1 (es) 2009-11-12
KR20100085116A (ko) 2010-07-28
US20090118344A1 (en) 2009-05-07
UA99746C2 (ru) 2012-09-25
AR068917A1 (es) 2009-12-16
UY31407A1 (es) 2009-05-29
ES2460951T3 (es) 2014-05-16
CN101827822B (zh) 2013-06-19
PA8800201A1 (es) 2009-05-15
CN101827822A (zh) 2010-09-08
EP2195298A1 (en) 2010-06-16
WO2009052226A1 (en) 2009-04-23
JP5517940B2 (ja) 2014-06-11
ECSP10010188A (es) 2010-06-29
DOP2010000115A (es) 2010-10-15
CA2699352C (en) 2016-06-21
US8486988B2 (en) 2013-07-16
CA2699352A1 (en) 2009-04-23
US20110196010A1 (en) 2011-08-11
TW200934485A (en) 2009-08-16
AU2008312529A1 (en) 2009-04-23
SG185327A1 (en) 2012-11-29
BRPI0818065A2 (pt) 2015-03-31
MX2010004286A (es) 2010-04-30
CO6280481A2 (es) 2011-05-20
CR11388A (es) 2010-10-05
US7947843B2 (en) 2011-05-24
JP2011500705A (ja) 2011-01-06
EP2195298B1 (en) 2014-02-19
RU2010119928A (ru) 2011-11-27
CL2008003090A1 (es) 2009-11-27

Similar Documents

Publication Publication Date Title
NO20076658L (no) Heteroarylbenzamidderivater for anvendelse som GLK aktivatorer ved behandling av diabetes
UA94390C2 (ru) Применение производных индолинонов, предназначенных для лечения или предупреждения идиопатического фиброза легких
UY27222A1 (es) Pirazolopirimidinas como agentes terapéuticos
NO20082112L (no) 3-Amino-2-arylpropylazaindoler og deres anvendelse
MX2010001574A (es) Ligandos del receptor cannabinoide.
NO20062020L (no) 1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika
TW200716628A (en) Novel compounds
HRP20090017T3 (hr) 3,11b-cis-dihidrotetrabenazin za liječenje proliferativnog oboljenja ili upale
BRPI0818065A8 (pt) Quimioterapêutco derivado de indazol cristalino
HRP20080552A9 (en) Benzimidazole derivative and use thereof
DOP2010000112A (es) Productos quimioterapeuticos cristalinos
ECSP10010175A (es) Productos quimioterapéuticos cristalinos
UA99487C2 (xx) Кристалічний хіміотерапевтичний засіб$кристаллическое химиотерапевтическое средство
CL2008003091A1 (es) Forma cristalina 1 de etanolato de n-(4-(3-amino-1h-indazol-4il)fenil)-n-(2-fluoro-5-metilfenil)urea. 1/4; composicion farmaceutica; y uso en el tratamiento de cancer en un mamifero.
BRPI0410704A (pt) uso de inibidor c-abl- tirosina quinase, pdgf-r- tirosina quinase, ou c-kit-tirosina quinase no tratamento da diabete
TH104744B (th) สารทางเคมีบำบัดที่เป็นผลึก
ATE482951T1 (de) Benzimidazolderivat und anwendung davon
ZA200908402B (en) N'- (Phenyl) - N- (Morpholin-4-YL-Pyridin-2-YL) -Pyrimidine-2, 4-Diamine derivatives as EphB4 kinase inhibitors for the treatment of proliferative conditions
TH104744A (th) สารทางเคมีบำบัดที่เป็นผลึก

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B25A Requested transfer of rights approved

Owner name: ABBVIE INC. (US)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.